Records containing: Neuroendocrine Tumors
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-17Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-11-12Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
-
CLINICAL_TRIALS study record update · 2025-11-04A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-10-28SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
-
CLINICAL_TRIALS study record update · 2025-10-20Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-09-23A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
-
CLINICAL_TRIALS study record update · 2025-09-22EchoTip AcuCore Post-Market Clinical Study
-
CLINICAL_TRIALS study record update · 2025-09-18A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-09-16An Open-Label Study of Surufatinib in Japanese Patients With Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-09-15A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies
-
CLINICAL_TRIALS study record update · 2025-09-10A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
-
CLINICAL_TRIALS study record update · 2025-09-10Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An Open-label, Multicenter, Randomized Phase III Trial Comparing Safety and Efficacy of Personalized Versus Non-personalized Radionuclide Therapy With 177Lu (Lutetium)-DOTATOC.
-
CLINICAL_TRIALS study record update · 2025-09-05A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours
-
CLINICAL_TRIALS study record update · 2025-09-04A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants Who Have Been Previously Treated With 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study
-
CLINICAL_TRIALS study record update · 2025-08-26Addressing Social Determinants of Health (SDOH) Among Metro Detroit Cancer Survivors: A Pilot Feasibility Study (The Resource Ready Study)
-
CLINICAL_TRIALS study record update · 2025-08-14A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (STOPNET)
-
CLINICAL_TRIALS study record update · 2025-07-24Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
-
CLINICAL_TRIALS study record update · 2025-07-22177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
-
CLINICAL_TRIALS study record update · 2025-07-14Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-07-10A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers
-
CLINICAL_TRIALS study record update · 2025-07-09Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-06-25Prognostic Interest of a Whole Body Dynamic PET Acquisition in Pre-therapeutic 68Ga-DOTATOC PET/CT for Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-06-13Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients
-
CLINICAL_TRIALS study record update · 2025-06-05Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
-
CLINICAL_TRIALS study record update · 2025-05-31A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors